Results 151 to 160 of about 8,952 (190)
Some of the next articles are maybe not open access.

Bullous pemphigoid in adolescence

Pediatric Dermatology, 2018
AbstractBullous pemphigoid (BP) is the most common autoimmune blistering disease affecting the elderly but is quite rare in childhood. The majority of pediatric cases have been reported during early childhood. Adolescence is divided into three phases: early (10‐13 years), middle (14‐17), and late (18‐21).
Aikaterini Patsatsi   +2 more
openaire   +2 more sources

Eosinophils in bullous pemphigoid

Panminerva Medica, 2021
Bullous pemphigoid (BP) is an autoimmune blistering disorder with substantial morbidity and mortality. BP is regarded as a disorder driven by IgG due to BP180 and BP230 IgG autoantibodies, yet, new advances highlight the function of eosinophils and IgE autoantibodies in BP.
Virginia A, Jones   +2 more
openaire   +2 more sources

The immunopathology of bullous pemphigoid

Clinics in Dermatology, 1987
Abstract The immunopathology of bullous pemphigoid features basement membrane zone (BMZ) deposition of immunoglobulin and complement and the presence of circulating immunoreactants. 1,2 The demonstration of linear subepidermal deposition of C3 and/or IgG is usually necessary to establish the diagnosis.
M J, Imber, G F, Murphy, R E, Jordon
openaire   +2 more sources

Bullous and cicatricial pemphigoid

Journal of Autoimmunity, 1991
Bullous pemphigoid (BP) and cicatricial pemphigoid are blistering mucocutaneous diseases characterized by detachment of the overlying epithelium from its stroma. IgG and complement components are deposited in all affected tissue at the level of blister formation--through the lamina lucida of the epithelium. The primary antibody response is of the IgG 4
G J, Anhalt, L H, Morrison
openaire   +2 more sources

Bullous pemphigoid in an infant

Australasian Journal of Dermatology, 1995
SUMMARYAn acral blistering eruption in a 10 week old baby was found on histology and direct immunofluorescence to be bullous pemphigoid. Circulating auto‐antibodies were not detected. He responded quickly to oral prednisolone and there have been no sequelae.
openaire   +2 more sources

[Physiopathology of bullous pemphigoid].

Annales de dermatologie et de venereologie, 2009
International ...
Doffoel-Hantz, V.   +5 more
openaire   +3 more sources

Erythrodermic bullous pemphigoid

Journal of the American Academy of Dermatology, 1993
REFERENCES L Korman N, Pemphigus. J AM ACAD DERMATOL 1988; 18:1219-38. 2. Barthelemy H, Frappaz A, Cambazard F, et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J AM ACAD DERMATOL 1988;18:1262-6, 3. ~evuz J. Plasmapheresis. In: Orfanos CE, Stadler R, GollDIck H, eds. Dermatology in five continents.
A, Saitoh   +5 more
openaire   +2 more sources

Bullous pemphigoid and penicillamine

Clinical and Experimental Dermatology, 1996
We describe a woman who developed bullous pemphigoid in association with penicillamine therapy. While pemphigus is a well-recognized complication of penicillamine, pemphigoid should also be considered in the differential diagnosis of bullous eruptions induced by this drug.
R, Weller, M I, White
openaire   +2 more sources

Purpuric Bullous Pemphigoid

The American Journal of Dermatopathology, 2015
Rare clinical variants of bullous pemphigoid (BP) include vesicular BP, dyshidrosiform BP, pemphigoid nodularis, seborrheic BP, pemphigoid vegetans, localized BP, erythrodermic BP, and juvenile BP. To our knowledge, this is the first report of an unusual case of purpuric BP. We present a case of 85-year-old white man who presented with a 2-week history
Maruska, Marovt   +1 more
openaire   +2 more sources

Treatment of Bullous Pemphigoid

The Journal of Dermatology, 2003
AbstractBullous pemphigoid (BP) is the most frequent auto‐immune blistering skin disease. Up to recently, it was treated with oral corticosteroids. High dose steroids are poorly tolerated in the elderly and probably contributed to the high mortality rates observed in several cohorts.
Juliette, Fontaine   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy